ABSTRACT
Alatrofloxacin mesylate is the L-alanyl-L-alanyl prodrug of trovafloxacin mesylate (the structure is shown in Fig. 1). It is intended for administration by intravenous infusion. Following intravenous administration, the alanine substituents in alatrofloxacin are rapidly hydrolyzed in vivo to yield trovafloxacin.
